ANIX Anixa Biosciences: רווח נקי למניה ב-12 החודשים האחרונים

The development of female oncology therapies at Anixa Biosciences, Inc. (ANIX) remains independent of economic cycles, demonstrating high macro-resilience. Business efficiency relies on a virtual model characterized by a minimal headcount and outsourced processes. This price chart reflects EPS dynamics, which currently stand at 10.00. The company's innovative image in cancer diagnostics confirms its authority among the world's leading scientists.
ANIX (Anixa): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Year-over-year (YoY) EPS growth (TTM) measures the percentage change in net income per share over the last twelve months relative to the same period last year. By analyzing YoY TTM earnings per share dynamics, an investor assesses the real efficiency of capital generation and the pace of business scaling. This calculation reveals hidden risks of frozen funds under tight monetary policy. For Anixa Biosciences, Inc. (ANIX), this indicator is critical, as it confirms the company's financial stability until it clears FDA filters and commercializes its vaccines.